02256.HK
Abbisko Cayman Limited
HKSE · Healthcare · Biotechnology · CN
HKD 8.77
−1.79%Margins
Gross margin
98.2%
EBITDA margin
-523.5%
EBIT margin
-532.7%
Net margin
-479.8%
FCF margin
-231.6%
-21.4%
Return on equity
-17.3%
Return on assets
-19.7%
Return on invested capital
0.04x
Asset turnover
-HKD 261.1M
Cash from operations
HKD 4.60
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026